See more : Kin Mining NL (KIN.AX) Income Statement Analysis – Financial Results
Complete financial analysis of IMARA Inc. (IMRA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of IMARA Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- China Changjiang Mining & New Energy Company, Ltd. (CHJI) Income Statement Analysis – Financial Results
- Soken Chemical & Engineering Co., Ltd. (4972.T) Income Statement Analysis – Financial Results
- Benjamin Hornigold Limited (BHD.AX) Income Statement Analysis – Financial Results
- EQ Inc. (EQ.V) Income Statement Analysis – Financial Results
- Severn Bancorp, Inc. (SVBI) Income Statement Analysis – Financial Results
IMARA Inc. (IMRA)
About IMARA Inc.
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 18.94M | 38.44M | 32.15M | 19.01M | 8.24M |
| General & Administrative | 15.33M | 13.00M | 9.54M | 5.11M | 2.44M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 15.33M | 13.00M | 9.54M | 5.11M | 2.44M |
| Other Expenses | -97.00K | -175.00K | -145.00K | 75.00K | 0.00 |
| Operating Expenses | 34.27M | 51.44M | 41.70M | 24.12M | 10.68M |
| Cost & Expenses | 34.27M | 51.44M | 41.70M | 24.12M | 10.68M |
| Interest Income | 943.00K | 233.00K | 483.00K | 578.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -69.39M | 99.00K | 97.00K | 33.00K | -660.00K |
| EBITDA | -68.66M | -51.34M | -41.60M | -24.08M | -11.34M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 730.00K | -51.44M | -41.70M | -24.12M | -10.68M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 846.00K | 58.00K | 338.00K | 653.00K | -660.00K |
| Income Before Tax | 1.58M | -51.38M | -41.36M | -23.46M | -11.34M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 88.00K | -233.00K | -483.00K | -578.00K | 0.00 |
| Net Income | 1.58M | -51.15M | -40.88M | -22.89M | -11.34M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.24 | -9.45 | -11.74 | -9.69 | -1.20 |
| EPS Diluted | 0.24 | -9.45 | -11.74 | -9.69 | -1.20 |
| Weighted Avg Shares Out | 6.57M | 5.42M | 3.48M | 2.36M | 9.44M |
| Weighted Avg Shares Out (Dil) | 6.57M | 5.42M | 3.48M | 2.36M | 9.44M |
Penny Stocks To Buy This Week? 7 Short Squeeze Stocks To Watch
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FCRD, KNBE, IMRA
3 Best Penny Stocks To Buy Before November According To Insiders
New to Trading Penny Stocks? Must Knows in 2022
Imara (IMRA) Stock Soars 35% on Merger Agreement
Imara: Potential Liquidation
Has IMARA (IMRA) Outpaced Other Medical Stocks This Year?
3 High Volume Penny Stocks To Watch Before Next Week
10 Top Penny Stocks With Unusual Options Activity This Week
Looking for Popular Penny Stocks to Buy? 3 to Watch Now
Source: https://incomestatements.info
Category: Stock Reports